Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|76|4|275-285

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.4, 2009-03, pp. : 275-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 23-30

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 147-151

Karger

Access to resources Recommend Favorite

Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 141-146

Karger

Access to resources Recommend Favorite